Introductory rate of $325 expires 2/10/12. Save $50 off the regular rate of $375. Click the sample link below to view the complete table of contents and select pages.

The top 30 Japanese pharma companies generated more than $102 billion in combined healthcare revenue for the fiscal year ended in March 2011, which was the same amount for the previous annual term. Healthcare R&D growth also was flat year over year, coming in at about $20 billion.

The following information is included for the Top 30 Japanese companies, which were determined based on their healthcare revenue generated during 2010:

- Each pipeline products’ chemical or substance composition, intended indication, clinical status, region of development, and developer/marketer

- Pipeline status details preclinical development, Phase I, Phase II, Phase III, and awaiting approval

- Region of development includes the U.S., Europe, and Japan

- Select 2010 and 2009 financial data such as revenue, net income, earnings per share, and R&D expenditure

The report overview includes news updates and overall status for the leading Japanese companies. The analysis details promising pipeline candidates, the R&D structure of each corporation, as well company management plans and goals.